Exploring epigenetics by Lechner, M
Could you begin by offering an overview of 
your principal research aims? 
The main aim of my research study is to 
understand the epigenetic and genetic basis of 
human papillomavirus (HPV)-associated head 
and neck cancer, a rapidly evolving cancer 
in the Western world. This is of particular 
interest, as patients with HPV-positive head 
and neck cancer have a better prognosis 
than patients with head and neck tumours 
caused by smoking and alcohol abuse. The 
described difference in the survival rates may 
be explained by alterations, in particular in 
the epigenome of tumour cells. This will guide 
the development of novel biomarkers for this 
deadly disease. 
What may be the reason for the rapid 
increase of HPV-associated head and 
neck cancer?
It may be that the epidemiology of the cancer 
is driven by population changes in sexual 
behaviour. In the UK, for example, a signifi cant 
increase in the proportion of people reporting 
oral sex occurred between 1990 and 2000.
Why has there not been an improvement in 
survival rates of head and neck cancer over 
the past three decades?
One of the main reasons for the poor survival 
rates is that this form of cancer, in particular 
oropharyngeal cancer, often causes no or 
unspecifi c symptoms at early disease stages. 
Hence, patients often present at advanced 
disease stages at which treatment is limited 
to palliative measures only in some cases. 
Biomarkers for early-stage disease do not 
exist and relatively few novel treatments have 
become available over the last decades.
How might epigenetic factors 
inﬂ uence HPV? 
Epigenetic processes may affect both the 
viral genome itself and the host cell genome. 
Modifi cation of normal epigenetic processes 
in the host occurs during viral infection: for 
example, compared with HPV-negative head 
and neck squamous cell carcinoma (HNSCC), 
HPV-positive tumours show less genome-wide 
hypomethylation. These epigenetic changes 
may occur through direct interactions between 
HPV proteins, eg. E2, E7, and the body’s own 
proteins involved in DNA methylation. Viral 
oncoproteins – in particular, E7 – can bind and 
regulate the enzymatic activity of an enzyme 
that methylates DNA (DNMT1). 
You have been using a new approach 
made possible by recent advances in DNA 
proﬁ ling. What is this new technique?
I used a method that was developed in the 
Beck lab by Dr Christina Thirlwell at the 
University College London (UCL) Cancer 
Institute. By applying a ligation step, it made 
it possible to use formalin-fi xed paraffi n-
embedded tumour material for large-scale 
DNA methylation array analysis. For the initial 
experiment, Illumina 27k arrays were used. I 
was then able to apply this method to analyse 
my samples with the new Illumina 450k 
methylation arrays, and validated this method 
by an immunoprecipitation technique coupled 
with next-generation sequencing (MeDIP-Seq).
Can you describe the implications of your 
HPV-positive and HPV-negative DNA 
methylation analysis results? How will this 
inform further research? 
My work has contributed to the 
understanding of epigenetic changes 
at oncogenic loci associated with the 
progression of HPV-positive and HPV-
negative HNSCC. These may explain the 
better outcome and survival of patients 
suffering from this distinct subtype. In the 
longer term, these data can be expected to 
be used for the identifi cation of potential 
diagnostic and prognostic markers, as well 
as putative therapeutic targets.
Do you collaborate with any other 
institutions, partners or organisations 
in conducting this research programme? 
How are they involved? 
In this fi eld of research, collaboration is 
key. I had the fortune to be trained in the 
Beck and Boshoff labs at the UCL Cancer 
Institute, and this allowed me to work 
in a fantastic environment with a team 
of enthusiastic and excellent scientists. 
Among many others, I am now mainly 
working with Dr Tim Fenton, who is a 
Rosetree Trust Fellow, and Dr Martin 
Forster, who is a Senior Lecturer at the UCL 
Cancer Institute. Together we are taking this 
project further. I am also collaborating with 
other institutions at UCL and UCL Hospitals 
as well as the University of Cambridge in 
order to investigate aspects of oral HPV 
infection, with the aim to identify a valid 
and reliable biomarker for oral HPV disease.
Could you give an insight into how you 
envision this research will progress over 
the next two to ﬁ ve years? What would 
you like to achieve?
My work at the moment mainly 
focuses on the integration of my 
research data with independent 
large-scale datasets. Over the 
next fi ve years, I will focus on 
the progression of oral HPV 
infection to oropharyngeal 
cancer and understanding 
the limiting steps in this 
process. This will allow the 
development of markers for 
risk stratifi cation and guide 
an indication for treatment of 
precancerous lesions.
Dr Matt Lechner leads the Head and Neck Cancer Genome and Epigenome Project. In an engaging 
conversation, he discusses his research into human papillomavirus-associated head and neck tumours
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Understanding 
HPV-associated tumours
A team at the University College London Cancer Institute is 
investigating the epigenetic basis of a form of head and neck cancer that is 
becoming increasingly common among the youth of the developed world
HEAD AND NECK cancer is the sixth most 
common cancer worldwide, with an incidence of 
600,000 cases per annum. As an umbrella term, 
head and neck squamous cell cancer (HNSCC) 
refers to cancers found at several locations, 
including the oral cavity, pharynx and larynx. 
Until the late 1990s, most cases were thought 
to be associated with alcohol and tobacco use 
only, but since then research has linked certain 
subtypes with human papillomavirus (HPV). 
While HPV was first recognised as the cause of 
cervical cancer and small numbers of genital 
cancers in the 1980s, it was not until 2007 that 
the World Health Organization’s International 
Agency for Research on Cancer in Lyons, France, 
declared there was sufficient evidence to 
determine HPV as a cause for a subset of head 
and neck cancers. Today, HPV-positive head 
and neck cancer is a rapidly emerging disease 
in many developed countries with rising trends 
particularly among the young. There are currently 
10,000 cases in the US alone each year and this 
number is projected to rise to 16,000 by 2030.
DISEASE DIFFERENTIATION
Research has shown that HPV-positive head 
and neck cancer is a completely different 
disease to the HPV-negative form. While 
the presenting symptoms are similar, factors 
driving pathogenesis are different. The main 
dissimilarities lie in their genetic mutation 
and gene expression statuses as well as their 
epidemiological factors and clinical features. 
This means that HPV-positive HNSCC represents 
a distinct molecular, epidemiologic and 
clinical entity.
The risk factors for both forms of cancer are 
equally divergent. While alcohol consumption 
and tobacco use are major causes of HPV-
negative tumours, HPV-associated head and 
neck cancers often occur in non-smokers who 
have a history of other lifestyle traits, such as 
a large number of sexual partners, especially in 
regards to oral sex.
Crucially, patients with HPV-positive tumours 
have a better prognosis than those with the 
HPV-negative variety, and tend to respond 
better to chemotherapy and radiotherapy, 
suggesting that it is important to stratify 
treatments according to the HPV status of 
the cancer.
ANALYSING EPIGENOMES
Dr Matt Lechner has driven forward the Head 
and Neck Cancer Epigenome Project at the 
University College London (UCL) Cancer 
Institute, UK, since 2009. He has focused on 
researching the genetic and epigenetic basis of 
HPV-positive head and neck cancer. 
In a previous study published in July 2013, 
Lechner et al presented a fuller understanding of 
the dynamics of HPV integration and its effect 
on both the viral and host methylomes. By 
conducting large-scale methylation analysis of 
HPV-positive and HPV-negative HNSCC, they 
determined the viral subtype to be HPV-16 in all 
cases. They also showed that HPV-16 integrates 
into the host genome at multiple random sites 
and that this process predominantly involves 
the transcriptional repressor gene (E2) in the 
viral genome. 
The aim of Lechner’s current project is to 
build an in-depth knowledge of virus-induced 
HNSCC carcinogenesis, potentially leading to 
the discovery of novel molecular markers for 
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DR MATTHIAS LECHNER graduated from 
the University of Innsbruck, Austria, as one 
of the youngest students nationwide. His 
MD thesis in the field of mass spectrometry 
was published and cited in various papers. 
He completed his family medicine residency 
training in the UK, Austria, and on a fully 
funded exchange fellowship programme 
in Indonesia, where he set up a global 
health project with the aim to decrease 
the high mortality from cancer in this 
region (www. yogyahealth.org). Lechner 
was awarded a prestigious Wellcome Trust 
Research Training Fellowship and completed 
a PhD on HPV-associated head and neck 
cancer at UCL. Thereafter, he started his 
surgical training in otolaryngology, currently 
working at the Royal National Throat, Nose 
and Ear Hospital, and continued his research 
work as a postdoctoral research fellow 
and later as a lecturer at the UCL Cancer 
Institute. He is a member of the Royal 
College of Surgeons of England and was 
awarded a Fellowship from the UK Higher 
Education Academy (FHEA) in 2013.
risk prediction, early diagnosis and therapeutic 
targets. The hope is that a deeper understanding 
of HPV-associated head and neck cancer could 
allow the therapeutic targeting of affected 
pathways for a stratified medicine approach. 
In order to discern why HPV-positive patients 
have a better prognosis than their HPV-negative 
counterparts, Lechner has analysed both 
epigenomes for differences in DNA methylation 
and integrated these with messenger RNA 
expression data. The epigenetic changes at 
oncogenic loci associated with progression to 
carcinoma – particularly in the HPV-positive 
form of the disease – are not well characterised 
and it is only recent technological advances 
that have enabled the study of these epigenetic 
variations at the genome level.
GROUNDBREAKING TECHNOLOGY
As frozen HNSCC samples are hard to source, 
Lechner was able to validate a method 
developed in-house that uses paraffin-fixed 
tumour samples. These samples are readily 
available and proved to be highly suitable for 
methylation analysis. In the study, formalin-
fixed paraffin-embedded HNSCCs were carefully 
dissected using a laser system, allowing the 
enrichment of tumour cells for subsequent 
analysis. DNA methylation profiles were then 
generated using two advanced techniques: an 
array-based method allowing the evaluation 
of the methylation state of over 480,000 
single methylation sites across the genome 
and a technique in which methylated DNA is 
immunoprecipitated and then sequenced.
As a result, the team was able to identify 
differences in the methylation profiles 
between HPV-positive and HPV-negative 
tumours. Unsupervised clustering over the 
differences in methylation profiles showed 
that the samples segregated according to their 
HPV status: “This was a clear indicator that 
both groups harbour a distinct methylation 
profile,” adds Lechner. “Interestingly, it showed 
that HPV-positive tumours are heterogenous 
with regard to this profile.” 
Lechner was able to cross-validate these 
methylation data into two sets of independent 
HPV-positive and HPV-negative samples. 
For the functional analysis, an HPV-negative 
HNSCC cell line was transduced with lentiviral 
constructs containing the two HPV oncogenes 
(E6 and E7) and the effects on methylation were 
assayed. Combinatorial ectopic expression of 
these oncogenes in an HPV-negative HNSCC cell 
line partially phenocopied the hypermethylation 
signature observed in HPV-positive tumours and 
established E6 as the main viral effector gene.
BEYOND HEAD AND NECK CANCERS
In order to further test the effect of HPV on 
DNA methylation, Lechner and colleagues 
integrated publicly available methylation 
data on cervical cancer (an example of HPV-
associated cancer) and lung cancer (an example 
of smoking-induced cancer) with the HPV-
positive and HPV-negative HNSCC samples. 
This was then used for multidimensional scaling 
of the datasets. 
An overlap of cervical cancer samples and HPV-
positive HNSCC samples was observed, which 
is likely to be due to the fact that HPV causes 
the same derangements in both tissues: “This 
confirmed the observed DNA methylation 
signature to be HPV-specific and tissue-
independent,” summarises Lechner.
TREATMENT FOR THE FUTURE
The biomarkers based on Lechner’s data, along 
with the recently obtained genetic, epigenetic 
and gene expression data on HPV-positive 
and HPV-negative HNSCC, will undoubtedly 
serve to advance the field of head and neck 
cancer diagnosis. 
For Lechner, the goal is that an understanding 
of the methylation differences between tumour 
types will allow patients to be stratified according 
to the HPV status of their cancer, ensuring they 
receive the best possible treatment. “In my 
ongoing research, I am integrating methylation 
data with genetic data and expression data, 
and validating findings in large independent 
datasets,” he explains. “These data will guide 
the development of diagnostic and prognostic 
biomarkers for this type of disease.”
The aim of Lechner’s current 
project is to build an in-depth 
knowledge of virus-induced 
head and neck squamous cell 
cancer carcinogenesis, potentially 
leading to the discovery of 
novel molecular markers for risk 
prediction, early diagnosis and 
therapeutic targets
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